Table I.
Patient characteristics.
| Characteristic | No. | % |
|---|---|---|
| Staging cohort | 95 | |
| Histology | ||
| PTCL, NOS | 35 | 36.8 |
| AITL | 17 | 18 |
| ALCL, ALK− or unknown | 12 | 12.6 |
| ALCL, ALK+ | 11 | 11.5 |
| NK/T cell lymphoma | 10 | 10.5 |
| ATLL | 7 | 7.3 |
| EATL | 3 | 3.1 |
| Disease state | ||
| Initial diagnosis | 77 | 81 |
| Relapsed disease | 18 | 19 |
| Gender | ||
| Male | 58 | 61 |
| Female | 37 | 39 |
| Interim restaging cohort | 50 | |
| Histology | ||
| PTCL-NOS | 19 | 38 |
| ALCL, ALK+ | 9 | 18 |
| NK/T cell lymphoma | 8 | 16 |
| AITL | 6 | 12 |
| ALCL, ALK− or unknown | 5 | 10 |
| EATL | 2 | 4 |
| ATLL | 1 | 1.42 |
| Treatment | ||
| Initial chemotherapy | ||
| CHOP | 19 | 38 |
| CHOP/ICE | 24 | 48 |
| Other* | 7 | 14 |
| Consolidative treatment | ||
| Autologous stem cell transplant | 22 | 44 |
| Allogeneic stem cell transplant | 7 | 14 |
PTCL, NOS, peripheral T cell lymphoma, not otherwise specified; AITL, angioimmunoblastic T cell lymphoma; ALCL, ALK−, anaplastic large cell lymphoma, anaplastic lymphoma kinase negative or unknown; ALCL, ALK+, anaplastic large cell lymphoma, anaplastic lymphoma kinase positive; NK/T cell lymphoma, natural killer/T cell lymphoma; ATLL, adult T cell leukemia/lymphoma, HTLV-1 associated; EATL, enteropathy associated T cell lymphoma; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; ICE, ifosfamide, carboplatin, etoposide.
Includes VACOP (etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin, n = 1), cyclophosphamide, pentostatin (n = 1), GND (gemcitabine, vinorelbine, doxorubicin, n = 1), IVAC (ifosfamide, etoposide, cytarabine, n = 1), SMILE (dexamethasone, methotrexate, ifosfamide, L-asparaginase, etoposide, n = 2), ICE/CBV (ifosfamide, carboplatin, etoposide/cyclophosphamide, carmustine, etoposide, n = 1).